MedTrace Logo

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

NCT00943852 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.

Conditions

Interventions

DRUG

losartan potassium

Single dose losartan 100 mg in one of five treatment periods

DRUG

Comparator: isosorbide mononitrate (ISMN)

Single dose ISMN 60 mg in one of five treatment periods

DRUG

Comparator: losartan + ISMN

Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods

DRUG

Comparator: losartan + ISMN

Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods

DRUG

Comparator: Placebo

Single dose placebo only in one of five treatment periods

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2006-12-31
Completion
2006-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943852 on ClinicalTrials.gov